News

The primary objective of the first phase III trial, named DORADO, is to determine if darusentan is effective in reducing systolic blood pressure in resistant hypertension patients currently

Petition requested FDA to require all in vitro diagnostic tests intended for use in drug or biologic therapeutic decision-making to be held to the same scientific and regulatory

Designated as TF3 and TF5, the new bispecific constructs were created using the Dock and Lock (DNL) method recently published in the Proceedings of the National Academy of

The data, presented in two abstracts at the American Society of Gene Therapy (ASGT) 2006 Annual Meeting, demonstrate that adeno-associated virus type 2 (AAV2), the delivery vector used

The phase I study assessed dose-limiting toxicities, maximum tolerated dose, and pharmacokinetics of AN-152 given once every three weeks in patients with gynaecological and breast cancers. Eight patients

In the study, which was designed to evaluate the efficacy of an oral formulation of SCV-07 in tuberculosis (TB), mice were infected with M. tuberculosis Erdman. Twelve days

Under the agreement, Glenmark will be responsible for preclinical development, will manage the clinical trials and manufacture the products; Glenmark will be responsible for filing the abbreviated new

Enzastaurin is an investigational, multi-targeted therapy that is currently the focus of two global phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin’s

Both phase II studies – Study 6 and Study 3 – met their primary endpoint of increased progression free survival (PFS) in patients with locally advanced or metastatic